Peter M George

List of Publications by Year in descending order

34 papers	2,270 citations	471509 17 h-index	454955 30 g-index
34 all docs	34 docs citations	34 times ranked	4003 citing authors

#	Article	IF	Citations
1	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	5.6	45
2	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	2.3	30
3	Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 522-524.	5.6	0
4	COVID-19 pneumonia and the pulmonary vasculature: a marriage made in hell. European Respiratory Journal, 2021, 58, 2100811.	6.7	4
5	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respiratory Research, 2021, 8, e001049.	3.0	28
6	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	6.7	11
7	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	10.7	198
8	Respiratory follow-up of patients with COVID-19 pneumonia. Thorax, 2020, 75, 1009-1016.	5.6	266
9	Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Medicine,the, 2020, 8, 807-815.	10.7	802
10	Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans. ERJ Open Research, 2020, 6, 00290-2019.	2.6	8
11	Hiatus hernia and interstitial lung abnormalities. European Respiratory Journal, 2020, 56, 2001679.	6.7	6
12	Contemporary Concise Review 2019: Interstitial lung disease. Respirology, 2020, 25, 756-763.	2.3	2
13	Dissecting the role of the small airways in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2020, 8, 529-531.	10.7	2
14	Defining a pathological role for the vasculature in the development of fibrosis and pulmonary hypertension in interstitial lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L431-L433.	2.9	9
15	King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. European Respiratory Journal, 2019, 54, 1900281.	6.7	37
16	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	6.7	20
17	Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2019, 7, 271-282.	10.7	168
18	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	6.7	32

#	Article	IF	Citations
19	Rapidly Progressive Cystic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 264-264.	5.6	2
20	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. Expert Review of Clinical Immunology, 2018, 14, 127-135.	3.0	8
21	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	2.3	39
22	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	10.7	145
23	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Research, 2018, 4, 00124-2017.	2.6	16
24	Restrictive lung defects: parenchymal, chest wall and neuromuscular. Thorax, 2018, 73, 989-991.	5.6	2
25	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Review of Clinical Pharmacology, 2017, 10, 483-491.	3.1	31
26	Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy. Pulmonary Circulation, 2017, 7, 643-653.	1.7	33
27	Hypoxic Challenge Testing for Fitness to Fly with Severe Asthma. Aerospace Medicine and Human Performance, 2016, 87, 571-574.	0.4	5
28	An emerging interstitial lung disease. Lancet Respiratory Medicine,the, 2016, 4, 762.	10.7	2
29	Letter by Reed et al Regarding Article, â€œProteomic Analysis Implicates Translationally Controlled Tumor Protein as a Novel Mediator of Occlusive Vascular Remodeling in Pulmonary Arterial Hypertensionâ€. Circulation, 2015, 131, e347.	1.6	0
30	Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. Circulation Research, 2014, 114, 677-688.	4.5	124
31	Use of interferon beta for acute respiratory distress syndrome: proceed with caution. Lancet Respiratory Medicine,the, 2014, 2, e2.	10.7	0
32	Endothelinâ€1 as a Mediator and Potential Biomarker for Interferon Induced Pulmonary Toxicity. Pulmonary Circulation, 2012, 2, 501-504.	1.7	19
33	Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 2012, 426, 486-491.	2.1	33
34	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143